At present, it is not known how a non-cancer SARS-CoV-2-infected cell could respond to MDM2 inhibitors, but their use has been recently proposed as a possible strategy for COVID-19 patients (Zauli et al., 2020; Zauli et al., 2022). This evidence concerns the gene MDM2 and COVID-19.